Abstract: Lesions supplied by abnormal aggregations of vascular tissue or neovascular tissues are treated with photodynamic therapy by application of photosensitizing agent followed by precisely directed and calibrated laser activation to induce photothrombosis within target vascular tissue. The treatment forms a blood clot within the supply vessels thereby reducing the blood supply to the target lesion. Treated tissues atrophy or recede with low regrowth of vessels. The lower energy levels required significantly reduce damage to the surrounding tissues.

Abstract: A topical gel formulation containing aminocaproic acid prevents secondary hemorrhage following hyphema without the adverse side effects associated with systemically delivered aminocaproic acid. Of ten human patients treated with the formulation, none have experienced a secondary hemorrhage and none have experienced adverse side effects. The topical gel formulation is prepared by a process which ensures sterility, a pH compatible with conditions in the aqueous humor, and optimum consistency. A permeation enhancer such as proparacaine can be incorporated into the gel during formulation and be used to enhance the transport of aminocaproic acid across the corneal epithelium.

Abstract: Persistent epithelial defects are effectively treated by topically applying a gelatinous composition containing either aminocaproic acid or tranexamic acid to the eye. In vivo results demonstrate improved healing of the epithelium and basement membrane complex. The gelatinous composition is prepared by a process that ensures sterility and proper pH conditions throughout the gel.

Abstract: A topical gel formulation containing aminocaproic acid prevents secondary hemorrhage following hyphema without the adverse side effects associated with systemically delivered aminocaproic acid. Of ten human patients treated with the formulation, none have experienced a secondary hemorrhage and none have experienced adverse side effects. The topical gel formulation is prepared by a process which ensures sterility, a pH compatible with conditions in the aqueous humor, and optimum consistency. A permeation enhancer such as proparacaine can be incorporated into the gel during formulation and be used to enhance the transport of aminocaproic acid across the corneal epithelium.

Abstract: A topical gel formulation containing aminocaproic acid prevents secondary hemorrhage following hyphema without the adverse side effects associated with systemically delivered aminocaproic acid. Of ten human patients treated with the formulation, none have experienced a secondary hemorrhage and none have experienced adverse side effects. The topical gel formulation is prepared by a process which ensures sterility, a pH compatible with conditions in the aqueous humor, and optimum consistency. A permeation enhancer such as proparacaine can be incorporated into the gel during formulation and be used to enhance the transport of aminocaproic acid across the corneal epithelium.